Candel Therapeutics (CADL) said Wednesday it released final survival data from its phase 2a trial of CAN-2409 in advanced non-small cell lung cancer patients resistant to immune checkpoint inhibitor treatment.
The study demonstrated positive results, with a median overall survival of 24.5 months in the evaluable patients, surpassing standard care outcomes.
Key findings include a median overall survival of 21.5 months in patients with progressive disease despite ICI therapy, compared to 9.8 to 11.8 months with standard docetaxel chemotherapy. Additionally, 37% of patients survived beyond two years after receiving CAN-2409, while 69% showed regression in uninjected tumors, demonstrating an abscopal effect. Non-squamous NSCLC patients had the best outcomes, with a median overall survival of 25.4 months, the company said.
Throughout the long-term study, CAN-2409 maintained a strong safety profile and was well-tolerated by patients, Candel Therapeutics said.
Candel shares rose 2.5% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。